Aldo-keto reductase 1C3 regulates prostaglandin signaling in breast cancer

TOXI 40

Michael C. Byrns, mbyrns@mail.med.upenn.edu, Seon Hwa Lee, Ling Duan, Ian A. Blair, and Trevor M. Penning. Department of Pharmacology, Center for Cancer Pharmacology, and Center of Excellence in Environmental Toxicology, University of Pennsylvania, 135 John Morgan Bldg, 3620 Hamilton Walk, Philadelphia, PA 19104
Aldo-keto reductase (AKR) 1C3 (prostaglandin F synthase) likely contributes to breast cancer through regulation of prostaglandin (PG) signaling. AKR1C3 stereo-specifically reduces PGH2 and PGD2 to form PGF2a and 9a,11b-PGF2. These isomers bind F prostanoid receptors and stimulate cell proliferation, angiogenesis, and invasion. AKR1C3 also prevents the non-enzymatic formation of anti-proliferative PGJ2 products from PGD2. We examined PG metabolism by homogenous recombinant AKR1C3 and by MCF-7 cells that over-express AKR1C3. This was accomplished with a radiometric method using [3H]-PGD2 and separation by TLC and a chiral HPLC/APCI/MS method that utilized pentafluorobenzyl derivatization to provide sensitive, stereoisomer-specific, PG detection. We observed rapid reduction of PGD2 to 11b-PGF2 by recombinant AKR1C3, which completely prevented PGJ2 product formation. Similarly MCF-7 cells expressing AKR1C3 exhibited increased formation of PGF2 isomers and decreased formation of PGJ2 products. AKR1C3 is therefore predicted to contribute to proliferative PG signaling and represents a target for chemoprevention of breast cancer. [Supported by NIH grants T32 DK007314-25 (M.C.B.), R01 CA90744 and P30 ES013508 (T.M.P.)]
 

Poster Session and Awards
6:00 PM-10:00 PM, Tuesday, August 21, 2007 BCEC -- 204 A/B, Poster

Sci-Mix
8:00 PM-10:00 PM, Monday, August 20, 2007 BCEC -- Exhibit Hall - B2, Sci-Mix

Division of Chemical Toxicology

The 234th ACS National Meeting, Boston, MA, August 19-23, 2007